Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.
Cancer Discov
; 13(1): 19-22, 2023 01 09.
Article
en En
| MEDLINE
| ID: mdl-36620884
ABSTRACT
SUMMARY:
In this issue, Hattori and colleagues capitalized on targeted small-molecule covalent inhibitors of one KRAS mutant with a G12C substitution and of other oncoproteins to create drug-peptide conjugates that serve as cancer neoantigens that prompt an immune response to oncogene-mutant cancer cells. This immunotherapy strategy can serve as an effective approach to overcome the treatment-induced resistance that limits the effectiveness of essentially all small molecule-based targeted anticancer drugs. See related article by Hattori et al., p. 132 (9).
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias
/
Antineoplásicos
Idioma:
En
Revista:
Cancer Discov
Año:
2023
Tipo del documento:
Article